CoChat

Prognosis and clinical presentation of BRCA2-associated breast cancer

Loman, N, Johannsson, O, Bendahl, P.-O, Dahl, N, Einbeigi, Z, Gerdes, A.-M, Borg, Å, Olsson, H · 2000 · European Journal of Cancer

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

54 female breast cancer patients from 22 families with BRCA2 germ line mutations from Sweden and Denmark were compared with 214 age- and date of diagnosis-matched controls identified among breast cancer patients from South Sweden. At diagnosis, BRCA2-associated cases were more often node-positive (N+). OR=1.9 (95% confidence interval (CI)=1.0-3.6; P=0.036), and were more often clinical stage IV: OR=4.6 (95% CI=1.3-17; P=0.021) than the controls. Bilateral disease was also more common among the BRCA2-associated cases: OR=2. 4 (95% CI=1.1-5.3; P=0.027). Breast cancer-specific survival (BCSS) was significantly worse among the BRCA2-associated cases: RR=2.0 (95% CI=1.2-3.4; P=0.010). When stage was corrected for in a multivariate analysis, BCSS was no longer significantly worse for the BRCA2-associated cases: RR=1.6 (95% CI=0.85-3.1). The corresponding effect after correction for bilateral disease was: RR=1.8 (95% CI=1.0-3.1; P=0.034). The unfavourable prognosis in BRCA2-associated breast cancer seems, to a great extent, to be a consequence of the higher clinical stage at diagnosis. The increased presence of bilateral cancers appears to have less impact on survival in this group of hereditary breast cancer. Data presented here needs to be taken into account when counselling healthy carriers of BRCA2 germ line mutations.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0959-8049(00)00098-8

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. Armes, 1999, Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers, Cancer Res., 59, 2011

Cited by

See all 46

Metadata

Authors
Loman, N., Johannsson, O., Bendahl, P.-O., Dahl, N., Einbeigi, Z., Gerdes, A.-M., Borg, Å., & Olsson, H.
Affiliations
  • Skåne University Hospital (SE)
  • Uppsala University (SE)
  • Sahlgrenska University Hospital (SE)
  • Odense University Hospital (DK)
Corresponding author
Loman, N
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2000-07
Volume
36
Issue
11
Pages
1365-1373
ISSN
0959-8049 (ISSN-L)
OpenAlex
W2121515794
Cited by
46
References
23
Citations by year
2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2018: 1 · 2016: 1 · 2015: 3 · 2014: 2 · 2012: 1
FWCI
2.53
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • European Journal of Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
Arvid Nilssons Fond
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
  • Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Keywords
BRCA2, hereditary breast cancer, germline mutations, prognosis, breast cancer-specific survival, stage at diagnosis, node-positive disease, bilateral breast cancer, genetic counseling
MeSH terms
Adult, Aged, Aged, 80 and over, Breast Neoplasms, Denmark, Female, Humans, Middle Aged, Neoplasm Proteins, Neoplasm Staging, Pedigree, Regression Analysis, Risk Factors, Sweden, Transcription Factors, Survival Rate, Survival Analysis, Case-Control Studies, Germ-Line Mutation, BRCA2 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognosis and clinical presentation of BRCA2-associated breast cancer. https://app.cochat.ai/papers/10.1016/s0959-8049(00)00098-8
The paper
Loman, N., Johannsson, O., Bendahl, P.-O., Dahl, N., Einbeigi, Z., Gerdes, A.-M., Borg, Å., & Olsson, H. (2000). Prognosis and clinical presentation of BRCA2-associated breast cancer. European Journal of Cancer. https://doi.org/10.1016/s0959-8049(00)00098-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.